Study of how liver disease affects two new medications
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–85 years old
- Either completely healthy with normal liver function, OR have chronic (long-lasting) liver disease that has been stable for at least 6 months
- Weigh at least 110 pounds (50 kg) and have a BMI between 18–42
- Able to use reliable birth control for at least 2 months after the study ends
- Have stable doses of any current medications for at least 2 weeks before screening
- No history of HIV, hepatitis B, or hepatitis C; no active drug or alcohol abuse in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug (AZD4144) is processed by the body in people with different levels of liver function. It aims to see if the drug is safe and how the liver affects its levels, which may help guide future dosing for patients with liver problems.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.